Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape
Open accessAbstract
Cancer immunotherapy is experiencing a renaissance spearheaded by immune checkpoint inhibitors (ICIs). This has spurred interest in 'upgrading' existing immunotherapies that previously experienced only sporadic success, such as dendritic cells (DCs) vaccines. In this review, we discuss the major molecular, immunological, and clinical determinants of existing first- and second-generation DC vaccines. We also outline the future trends for next-generation DC vaccines and describe their major hallmarks and prerequisites necessary for high anticancer efficacy. In addition, using existing data we compare DC vaccines with ICIs targeting CTLA4, PD1, and PD-L1, and argue that in various contexts next-generation DC vaccines are ready to meet some challenges currently confronting ICIs, thereby raising the need to integrate DC vaccines in future combinatorial immunotherapy regimens.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
RNA vaccines have exhibited encouraging results in both infection therapy and cancer immunotherapy.
“RNA vaccines, for example, have exhibited encouraging results in both infection therapy and cancer immunotherapy.[6, 7, 11–15]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · see citing works
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · see citing works
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,771 · see citing works
Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavecchia, A., & Colonna, M. (1999) · Nature Medicine · doi:10.1038/11360 · Cited by 1,734 · see citing works
T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases
Mempel, T. R., Henrickson, S. E., & von Andrian, U. H. (2004) · Nature · doi:10.1038/nature02238 · Cited by 1,720 · see citing works
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580 · see citing works
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · see citing works
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?
Lutz, M. B., & Schuler, G. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02281-0 · Cited by 1,349 · see citing works
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · see citing works
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285 · see citing works
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216 · see citing works
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,176 · see citing works
Jonuleit, H., Kühn, U., Müller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J. X. F. R., & Enk, A. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271209 · Cited by 1,163 · see citing works
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., den Eynde, B. J. V., van der Bruggen, P., & Boon, T. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3670 · Cited by 1,142 · see citing works
Self-citationType I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081 · see citing works
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074 · see citing works
Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works
Dendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2016) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 926 · see citing works
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 861 · see citing works
Ribas, A., Kefford, R. F., Marshall, M. A., Punt, C. J. A., Haanen, J. B. A. G., Mármol, M., Garbe, C., Gogas, H. J., Schachter, J., Linette, G. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6112 · Cited by 802 · see citing works
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W. R., Huber, C., Parmiani, G., Scholl, S., Thatcher, N. J., Wagstaff, J., Zielinski, C. C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 773 · see citing works
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity
Sancho, D., Joffre, O. P., Keller, A. M., Rogers, N. C., Martínez, D., Hernanz-Falcón, P., Rosewell, I., & Sousa, C. R. E. (2009) · Nature · doi:10.1038/nature07750 · Cited by 750 · see citing works
Hodi, F. S., Hwu, W., Kefford, R. F., Weber, J. S., DAUD, A. I., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 735 · see citing works
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., OSSENDORP, F. A., van Hall, T., & Melief, C. J. M. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.16 · Cited by 709 · see citing works
Clinical use of dendritic cells for cancer therapy
Anguille, S., Smits, E., Lion, E., Tendeloo, V. F. V., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 707 · see citing works
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697 · see citing works
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalPreprint
Brown, S. D., Warren, R. M., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H., & Holt, R. A. (2014) · Genome Research · doi:10.1101/gr.165985.113 · Cited by 589 · see citing works
Microbiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478 · see citing works
Acquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.2 · Cited by 468 · see citing works
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500090102 · Cited by 458 · see citing works
Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity
Aaes, T. L., Kaczmarek, A., Delvaeye, T., Craene, B. D., Koker, S. D., Heyndrickx, L., Delrue, I., Taminau, J., Wiernicki, B., Groote, P. D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.037 · Cited by 448 · see citing works
Self-citationAssociation of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
Joseph, C. G., Darrah, E., Shah, A. A., Skora, A. D., Casciola-Rosen, L. A., Wigley, F. M., Boin, F., Fava, A., Thoburn, C. J., Kinde, I., et al. (2013) · Science · doi:10.1126/science.1246886 · Cited by 433 · see citing works
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apétoh, L., Baert, T., Birge, R. B., Pedro, J. M. B., Breckpot, K., Brough, D., Chaurio, R. A., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 409 · see citing works
Self-citationDudek, A. M., Martin, S., Garg, A. D., & Agostinis, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00438 · Cited by 394 · see citing works
Self-citationDendritic Cell–Based Immunotherapy: State of the Art and Beyond
Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M., & Figdor, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1399 · Cited by 379 · see citing works
Tel, J., Aarntzen, E. H. J. G., Baba, T., Schreibelt, G., Schulte, B. M., Benítez‐Ribas, D., Boerman, O. C., Croockewit, S., Oyen, W. J. G., van Rossum, M. M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2583 · Cited by 351 · see citing works
Self-citationWilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., & Neyns, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4121 · Cited by 312 · see citing works
Schreibelt, G., Tel, J., Sliepen, K., Benítez‐Ribas, D., Figdor, C. G., Adema, G. J., & de Vries, I. J. M. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0833-1 · Cited by 270 · see citing works
Garg, A. D., Vandenberk, L., Koks, C., Verschuere, T., Boon, L., Van Gool, S. W., & Agostinis, P. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0105 · Cited by 270 · see citing works
Self-citationLaoui, D., Keirsse, J., Morias, Y., van Overmeire, E., Geeraerts, X., Elkrim, Y., Kiss, M., Bolli, E., Lahmar, Q., Sichien, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms13720 · Cited by 255 · see citing works
Chiang, C. L.-L., Benencia, F., & Coukos, G. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.02.004 · Cited by 246 · see citing works
Vacchelli, E., Vitale, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Cremer, I., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 246 · see citing works
Checkpoint blocking antibodies in cancer immunotherapy
Kyi, C., & Postow, M. A. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.10.015 · Cited by 245 · see citing works
Schreibelt, G., Bol, K. F., Westdorp, H., Wimmers, F., Aarntzen, E. H. J. G., Boer, T. D., van de Rakt, M. W. M. M., Scharenborg, N. M., de Boer, A. J., Pots, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2205 · Cited by 243 · see citing works
Sandoval, F., Terme, M., Nizard, M., Badoual, C., Bureau, M., Freyburger, L., Clémеnt, O., Marcheteau, E., Gey, A., Fraisse, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004888 · Cited by 238 · see citing works
Germeau, C., Ma, W., Schiavetti, F., Lurquin, C., Henry, E., Vigneron, N., Brasseur, F., Lethé, B., Plaen, E. D., Velu, T. J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041379 · Cited by 232 · see citing works
Self-citationMutational Landscape and Sensitivity to Immune Checkpoint Blockers
Chabanon, R. M., Pedrero, M., Lefèbvre, C., Marabelle, A., Soria, J., & Postel-Vinay, S. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 232 · see citing works
Garg, A. D., Ruysscher, D. D., & Agostinis, P. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1069938 · Cited by 229 · see citing works
Self-citationDraube, A., Klein-González, N., Mattheus, S., Brillant, C., Hellmich, M., Engert, A., & von Bergwelt‐Baildon, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018801 · Cited by 213 · see citing works
Koks, C., Garg, A. D., Ehrhardt, M., Riva, M., Vandenberk, L., Boon, L., Vleeschouwer, S. D., Agostinis, P., Graf, N. M., & Gool, S. V. (2014) · International Journal of Cancer · doi:10.1002/ijc.29202 · Cited by 206 · see citing works
Self-citationThe Human Vaccines Project: A roadmap for cancer vaccine development
Romero, P. J., Banchereau, J., Bhardwaj, N., Cockett, M. I., Disis, M. L., Dranoff, G., Gilboa, E., Hammond, S. A., Hershberg, R. D., Korman, A. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf0685 · Cited by 194 · see citing works
Dendritic Cell-Targeted Vaccines
Cohn, L. B., & Delamarre, L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00255 · Cited by 191 · see citing works
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
Braun, D. A., Burke, K. P., & Allen, E. M. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0066 · Cited by 177 · see citing works
Antigens for cancer immunotherapy
Neller, M. A., López, J. A., & Schmidt, C. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.09.006 · Cited by 166 · see citing works
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
Anguille, S., Smits, E., Bryant, C. E., Acker, H. H. V., Goossens, H., Lion, E., Fromm, P. D., Hart, D. N. J., Tendeloo, V. F. V., & Berneman, Z. N. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009456 · Cited by 152 · see citing works
Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma
Inogés, S., Rodrı́guez-Calvillo, M., Zabalegui, N., de Cerio, A. L.-D., Villanueva, H., Soria, E., Suárez, L., Rodríguez‐Caballero, A., Pastor, F., García‐Muñoz, R., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj358 · Cited by 150 · see citing works
Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21494 · Cited by 149 · see citing works
Constantino, J., Gomes, C. M. F., Falcão, A. C., Cruz, M. T., & Neves, B. M. (2015) · Translational research · doi:10.1016/j.trsl.2015.07.008 · Cited by 147 · see citing works
Zappasodi, R., Pupa, S. M., Ghedini, G. C., Bongarzone, I., Magni, M., Cabras, A. D., Colombo, M. P., Carlo‐Stella, C., Gianni, A. M., & Nicola, M. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1825 · Cited by 139 · see citing works
Henrickson, S. E., Perro, M., Loughhead, S. M., Senman, B. C., Stutte, S., Quigley, M. M., Alexe, G., Iannacone, M., Flynn, M. P., Omid, S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.034 · Cited by 138 · see citing works
Garg, A. D., Romano, E., Rufo, N., & Agostinis, P. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.5 · Cited by 131 · see citing works
Self-citationKong, Y.-C. M., & Flynn, J. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00206 · Cited by 124 · see citing works
Garg, A. D., Vandenberk, L., Fang, S., Fasche, T., Van Eygen, S., Maes, J., Van Woensel, M., Koks, C., Vanthillo, N., Graf, N., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.15 · Cited by 120 · see citing works
Self-citationDendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress?
Butterfield, L. H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00454 · Cited by 118 · see citing works
Prue, R. L., Vari, F., Radford, K. J., Tong, H., Hardy, M. Y., D’Rozario, R., Waterhouse, N. J., Rossetti, T. R., Coleman, R., Tracey, C., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000063 · Cited by 105 · see citing works
Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system
Ciampricotti, M., Hau, C., Doornebal, C. W., Jonkers, J., & de Visser, K. E. (2012) · Nature Medicine · doi:10.1038/nm.2652 · Cited by 104 · see citing works
Kersten, K., Salvagno, C., & de Visser, K. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00516 · Cited by 89 · see citing works
NK Cells: Key to Success of DC-Based Cancer Vaccines?
Lion, E., Smits, E., Berneman, Z. N., & Tendeloo, V. F. V. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0122 · Cited by 87 · see citing works
Garg, A. D., Elsen, S., Krysko, D. V., Vandenabeele, P., de Witte, P., & Agostinis, P. (2015) · Oncotarget · doi:10.18632/oncotarget.4754 · Cited by 87 · see citing works
Self-citationHow many dendritic cells are required to initiate a T-cell response?
Celli, S., Day, M., Müller, A. J., Molina-Parı́s, C., Lythe, G., & Bousso, P. (2012) · Blood · doi:10.1182/blood-2012-01-408260 · Cited by 84 · see citing works
Dendritic cell-based therapeutic cancer vaccines: past, present and future
Ahmed, M. S., & Bae, Y. (2014) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2014.3.2.113 · Cited by 73 · see citing works
Trial watch: Dendritic cell-based anticancer therapy
Bloy, N., Pol, J. G., Aranda, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Tartour, É., Špíšek, R., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.963424 · Cited by 72 · see citing works
Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment
Dewitte, H., Verbeke, R., Breckpot, K., Smedt, S. C. D., & Lentacker, I. (2014) · Nano Today · doi:10.1016/j.nantod.2014.10.001 · Cited by 71 · see citing works
Garg, A. D., Vandenberk, L., Woensel, M. V., Belmans, J., Schaaf, M. B. E., Boon, L., Vleeschouwer, S. D., & Agostinis, P. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1295903 · Cited by 71 · see citing works
Self-citationYang, D.-H., Park, J., Jin, C.-J., Kang, H.-K., Nam, J., Rhee, J., Kim, Y.-K., Chung, S.-Y., Choi, S.-J.-N., Kim, H.-J., et al. (2009) · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis · doi:10.1016/j.leukres.2008.09.006 · Cited by 69 · see citing works
Advances in immunotherapy for treatment of lung cancer.
Alvarez, J. G. B., González‐Cao, M., Karachaliou, N., Santarpía, M., Viteri, S., Teixidó, C., & Rosell, R. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0032 · Cited by 66 · see citing works
Overwijk, W. W., Wang, E., Marincola, F. M., Rammensee, H., & Restifo, N. P. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-11 · Cited by 61 · see citing works
Lim, D., Kim, J., Lee, D.-S., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0325-0 · Cited by 53 · see citing works
Learning from the “tsunami” of immune checkpoint inhibitors in 2015
Kourie, H. R., Awada, G., & Awada, A. H. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.017 · Cited by 42 · see citing works
Advances in immunotherapy for treatment of lung cancer
Jean, Bustamante, Álvarez, et al. (2015) · 癌症生物学与医学：英文版 · Cited by 40 · see citing works
Advances in the understanding of cancer immunotherapy
Shore, N. D. (2014) · British Journal of Urology · doi:10.1111/bju.12692 · Cited by 37 · see citing works
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
Dillman, R. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1244149 · Cited by 32 · see citing works
Eggermont, A. M. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2377 · Cited by 29 · see citing works
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope
Textor, A., Schmidt, K., Kloetzel, P., Weißbrich, B., Pérez, C., Charo, J., Anders, K., Sidney, J., Sette, A., Schumacher, T. N., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160636 · Cited by 28 · see citing works
Active dendritic cell immunotherapy for glioblastoma: Current status and challenges
Polyzoidis, S., Tuazon, J., Brazil, L., Beaney, R. P., Al‐Sarraj, S., Doey, L. J., Logan, J., Hurwitz, V., Jarosz, J., Bhangoo, R. S., et al. (2014) · British Journal of Neurosurgery · doi:10.3109/02688697.2014.994473 · Cited by 24 · see citing works
Personalized tumor vaccines keep cancer in check
Kaiser, J. (2017) · Science · doi:10.1126/science.356.6334.122 · Cited by 23 · see citing works
T-cell checkpoint inhibitors in metastatic renal cell carcinoma
Grünwald, V. (2015) · Current Opinion in Urology · doi:10.1097/mou.0000000000000199 · Cited by 8 · see citing works
Recent advances in the management of renal cell carcinoma
Molina, A. M., & Nanus, D. M. (2016) · F1000Research · doi:10.12688/f1000research.7935.1 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Myeloid cell heterogeneity in cancer: not a single cell alike
Kiss, M., Van Gassen, S., Movahedi, K., Saeys, Y., & Laoui, D. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.008 · Cited by 159 · see citing works
Type I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124 · see citing works
Self-citationZhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000474 · Cited by 112 · see citing works
Type I interferons and endoplasmic reticulum stress in health and disease
(2020) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.10.004 · Cited by 83 · see citing works
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82 · see citing works
Mankor, J. M., Disselhorst, M. J., Poncin, M., Baas, P., Aerts, J. G. J. V., & Vroman, H. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.103040 · Cited by 45 · see citing works
- Authors
- Garg, A. D., Coulie, P. G., Van den Eynde, B. J., & Agostinis, P.
- Affiliations
- KU Leuven (BE)
- de Duve Institute (BE)
- Corresponding author
- Garg, Abhishek D.
- Agostinis, Patrizia
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 38
- Issue
- 8
- Pages
- 577-593
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W2624407975
- Cited by
- 340
- References
- 100
- Citations by year
- 2026: 11 · 2025: 26 · 2024: 31 · 2023: 29 · 2022: 45 · 2021: 50 · 2020: 60 · 2019: 55 · 2018: 24 · 2017: 8
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Trends in Immunology (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- Funders
- FWO (G060713N, G076617N)
- KU Leuven (C16/15/073)
- Belgian State (IAP7/32)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- dendritic cell vaccine, cancer immunotherapy, immune checkpoint inhibitors, CTLA-4, PD-1, PD-L1, combination immunotherapy, next-generation vaccines, vaccine design, anticancer efficacy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Immunotherapy, Neoplasms, Chemotherapy, Adjuvant, Cancer Vaccines, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
